Credit Suisse analyst Dominic Lunn raised the firm’s price target on Grifols to EUR 13.50 from EUR 11 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRFS:
- Grifols price target raised to EUR 12 from EUR 10 at Deutsche Bank
- Grifols accelerates healthcare innovation with Google Cloud’s AI, analytics
- Grifols price target raised to EUR 11.50 from EUR 10 at Barclays
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients